Literature DB >> 14983983

GPI-1485 (Guilford).

Victoria L Marshall1, Donald G Grosset.   

Abstract

GPI-1485 is a neuroimmunophilin ligand that binds to FK-506-binding proteins and is under development by Guilford for the potential treatment of erectile dysfunction following nerve injury during prostate resection and Parkinson's disease. In August 2002, phase II clinical trials investigating GPI-1485 for Parkinson's disease commenced, and in November 2003, further phase II trials commenced for post-prostatectomy erectile dysfunction.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14983983

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

Review 1.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

Review 2.  Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration.

Authors:  Melanie Gerard; Angélique Deleersnijder; Jonas Demeulemeester; Zeger Debyser; Veerle Baekelandt
Journal:  Mol Neurobiol       Date:  2011-05-07       Impact factor: 5.590

3.  Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities.

Authors:  Benfang Ruan; Kevin Pong; Flora Jow; Mark Bowlby; Robert A Crozier; Danni Liu; Shi Liang; Yi Chen; Mary Lynn Mercado; Xidong Feng; Frann Bennett; David von Schack; Leonard McDonald; Margaret M Zaleska; Andrew Wood; Peter H Reinhart; Ronald L Magolda; Jerauld Skotnicki; Menelas N Pangalos; Frank E Koehn; Guy T Carter; Magid Abou-Gharbia; Edmund I Graziani
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-27       Impact factor: 11.205
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.